Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kisspeptin-10 Insulin Secretion in Men
NCT03771326Phase 3Completed
- Sponsor
- Quaid-i-Azam University
- Start
- Oct 2013
- Primary completion
- Nov 2013
- Modality
- Modified Peptides, Native Peptides
01
Overview
Phase 3, open-label trial of kisspeptin 112-121 in obesity (2 arms), sponsored by Quaid-i-Azam University. Primary endpoint: Changes in the response of insulin secretion to acute exogenous kisspeptin administration at 120 months. Started Oct 2013; status: completed.
02
Drugs
kisspeptin 112-121
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03771326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03771326.